Grand Pharmaceutical Says CBT-001 Meets Primary Endpoint in Phase III Trial
Grand Pharmaceutical said CBT-001 met the primary endpoint in a Phase III trial for pterygium.
Related stories
Toyota Motor Shares Hit 9-week High
Toyota Motor shares increased to 3176.00 JPY, the highest since September 2026. Over the past 4 weeks, Toyota Motor gained 9.63%, and in the last 12 months, it increased 4.34%.
L impact | EQUITY | Nov 05, 2026, 12:24 AM UTC
Seaport Entertainment Group Reports Quarterly Results
Seaport Entertainment Group reported results for the quarter ended September 30.
M impact | EQUITY | Nov 05, 2026, 12:15 AM UTC
Gold Royalty Reports Record Q3 and Nine-Month Results
Gold Royalty maintained 2026 guidance of 7.5K–9.3K GEOs.
M impact | EQUITY | Nov 05, 2026, 12:14 AM UTC
Sony Group shares rise 8%
M impact | EQUITY | Nov 05, 2026, 12:12 AM UTC
Lotte Energy Materials Swings to Q3 Net Profit of KRW 70.4 Billion
M impact | EQUITY | Nov 05, 2026, 12:12 AM UTC
Advantest shares extend decline, falling as much as 8.8%
M impact | EQUITY | Nov 05, 2026, 12:12 AM UTC